| BTF3P11 |
|
basic transcription factor 3 pseudogene 11
|
|
|
0.519 |
0.731 |
| CECR |
|
cat eye syndrome chromosome region
|
|
|
0.599 |
0.731 |
| HLA-DRB2 |
|
major histocompatibility complex, class II, DR beta 2 (pseudogene)
|
|
|
0.861 |
0.269 |
| HLA-DRB6 |
|
major histocompatibility complex, class II, DR beta 6 (pseudogene)
|
|
|
0.821 |
0.308 |
| HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
| IGH |
|
immunoglobulin heavy locus
|
|
|
0.473 |
0.654 |
| MS |
|
multiple sclerosis
|
|
|
0.599 |
0.692 |
| NM |
|
neutrophil migration
|
|
|
0.473 |
0.808 |
| TRBV20OR9-2 |
|
T cell receptor beta variable 20/OR9-2 (non-functional)
|
|
|
0.403 |
0.923 |
| CDR3 |
|
Cerebellar degeneration-related autoantigen-3
|
|
|
0.472 |
0.808 |
| TAM |
|
Myeloproliferative syndrome, transient (transient abnormal
|
|
|
0.528 |
0.731 |
| LILRB2 |
|
leukocyte immunoglobulin like receptor B2
|
|
1.3E-14 |
0.623 |
0.615 |
| PART1 |
|
prostate androgen-regulated transcript 1
|
|
|
0.483 |
0.885 |
| IGHV3OR16-7 |
|
immunoglobulin heavy variable 3/OR16-7 (pseudogene)
|
|
|
0.566 |
0.654 |
| IGHV3-69-1 |
|
immunoglobulin heavy variable 3-69-1 (pseudogene)
|
|
|
0.561 |
0.654 |
| IGHV3-52 |
|
immunoglobulin heavy variable 3-52 (pseudogene)
|
|
|
0.674 |
0.423 |
| MBL3P |
|
mannose-binding lectin family member 3, pseudogene
|
|
|
0.518 |
0.769 |
| IBD5 |
|
inflammatory bowel disease 5
|
|
|
0.705 |
0.538 |
| GAS5 |
|
growth arrest specific 5
|
|
|
0.497 |
0.808 |
| ERVK-6 |
|
endogenous retrovirus group K member 6, envelope
|
|
|
0.521 |
0.808 |
| HT |
|
Hashimoto thyroiditis
|
|
|
0.505 |
0.731 |
| HCG27 |
|
HLA complex group 27
|
|
2.3E-02 |
0.805 |
0.346 |
| COPD |
|
Pulmonary disease, chronic obstructive, severe early-onset
|
|
|
0.456 |
0.885 |
| H3P44 |
|
H3 histone pseudogene 44
|
|
|
0.636 |
0.462 |
| LINC01193 |
|
long intergenic non-protein coding RNA 1193
|
|
|
0.565 |
0.692 |